Antiproliferative effect of 1α,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation

Endocrinology

Volumn 139, Issue 3, 1998, Pages 1197-1207

  Zhuang, Sen Hong ^a   Burnstein, Kerry L ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CYCLINE; DNA FRAGMENT; PHOSPHOTRANSFERASE; PROPIDIUM IODIDE; PROTEIN P21; VITAMIN D RECEPTOR; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; CDK2 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DNA BINDING PROTEIN; PROTEIN SERINE THREONINE KINASE; RETINOBLASTOMA BINDING PROTEIN 1; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR DP1; TRANSCRIPTION FACTOR E2F;

ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; GROWTH INHIBITION; HOMEOSTASIS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHESIS; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROSTATE CANCER; RETINOBLASTOMA; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; MALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROSTATE TUMOR;

ANTINEOPLASTIC AGENTS; CALCITRIOL; CARRIER PROTEINS; CDC2-CDC28 KINASES; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; CYCLINS; DNA FRAGMENTATION; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; G1 PHASE; HUMANS; MALE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR DP1; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 85047680777     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.139.3.5770     Document Type: Article

References (40)

1. Reichel H, Koeffler KA, Norman AW 1989 The role of vitamin D endocrine system in health and diseases. N Engl J Med 320:980-991
2. Walters M 1992 Newly identified actions of the vitamin D endocrine system. Endocr Rev 13:719-764
3. Bickle DD 1992 Clinical counterpoint: vitamin D: new actions, new analogs, new therapeutic potential. Endocr Rev 13:765-784
4. Schwartz GG, Hulka BS 1990 Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 10:1307-1312
5. Hanchette CL, Schwartz GG 1992 Geographic patterns of prostate cancer mortality: evidence for a protective effect of ultraviolet radiation. Cancer 70:2861-2869
6. Schwartz GG, Oeler TA, Uskokovic MR, Bahnson RR 1994 Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. Anticancer Res 14:1077-1082
7. 3 receptors and actions in human prostate cancer cell lines. Endocrinology 132:1952-1960
8. 3 on primary cultures of human prostatic cells. Cancer Res 54:805-810
9. 3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1:997-1003
10. Tsai MJ, O'Malley BW 1994 Molecular mechanisms of action of steroid/ thyroid receptor superfamily members. Ann Rev Biochem 63:451-486
11. Glass CK 1994 Differential recognition of target genes by nuclear receptor monomers, dimers, and heterodimers. Endocr Rev 15:391-407
12. 3 are mediated exclusively through the genomic signaling pathway. Endocrinology 137:1554-1561
13. Zhuang SH, Schwartz GG, Cameron D, Burnstein KL 1997 Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol 126:83-90
14. Hedlund TE, Moffatt KA, Miller GJ 1996 Vitamin D receptor expression is required for growth modulation by 1,25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA 31. J Steroid Biochem Mol Biol 58:277-288
15. 3-resistant MCF-7 cell line. Endocrinology 137:400-409
16. Pols HAP, Birkenhäger JC, Foekenes Van Leeuwen, JPTNM 1990 Vitamin D: a modulator of cell proliferation and differentiation. J Steroid Biochem Mol Biol 37:873-876
17. Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP 1996 Transcriptional activation of the CDK inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 10:142-153
18. Loop SM, Rozanski TA, Ostenson RC 1993 Human primary prostate tumor cell line, AlVA 31. A new model of studying the hormonal regulation of prostate tumor growth. Prostate 22:93-107
19. Hotoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP 1983 LNCaP model of human prostatic carcinoma. Cancer Res 43:1809-1818
20. Tilley WD, Wilson CM, Marcelli M, McPhaul MJ 1990 Androgen receptor gene expression in human prostate cancer cell lines. Cancer Res 15:5382-5386
21. Locken MR, Brady J 1989 The adenovirus EIIA enhancer: analysis of regulatory sequences and changes in binding activity of ATF and E2F following adenovirus infection. J Biol Chem 264:6572-6579
22. Lees JA, Saito M, Vidal M, Valentine M, Look T, Harlow E, Dyson N, Helen K 1993 The retinoblastoma protein binds to a family of E2F transcription factor. Mol Cell Biol 13:7813-7825
23. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B 1993 WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825
24. Sambrook J, Fritsch EF, Maniatis T 1989 Molecular cloning: a laboratory manual, ed. 2, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp 16.66-16.67
25. Gorman CM, Moffat LF, Howard BH 1982 Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol 2:1044-1051
26. Baker AR, McDonell DP, Hughes M, Crisp TM, Mangelsdorf DJ, Haussler MR, Pike JW, Shine J, O'Malley BW 1988 Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci USA 85:3294-3298
27. Wecksler WR, Norman AW 1979 An hydroxylapatite batch assay for the quantitation of 1alpha,25-dihydroxyvitamin D3-receptor complexes. Anal Biochem 92:314-323
28. Berchem GJ, Bosseler M, Sugars LY, Voeller HJ, Zeitlin S, Gelmann EP 1995 Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res 55:735-738
29. Eltsner E, Linker-Isreali SM, Said J, Umiel T, De Vos S, Shintaku IP, Heber D, Binderup L, Uskokovic M, Koeffler H 1995 20-epi-vitamin D3 analogues: a novel class of potent inducers of differentiation of human breast cancer cell lines. Cancer Res 55:2822-2830
30. Blutt SE, Allegretto EA, Pike JW, Weigel NL 1997 1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology 138:1491-1497
31. Sherr CJ 1996 Cancer cell cycles. Science 274:1672-1677
32. Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, Upadhya P 1992 The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3. Cancer Res 52:515-52
33. Weinberg RA 1995 The retinoblastoma protein and cell cycle control. Cell 81:323-330
34. Bookstein R, Shew JY, Chen PL, Scully P, Lee WH 1990 Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247:712-715
35. Wang QM, Jones JB, Studzinski GP 1996 Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res 56:264-267
36. Bukholm IK, Nesland JM, Karesen R, Jacobsen U, Borresen AL 1997 Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas. J Pathol 181:140-145
37. Matsushita K, Kobayashi S, Kato M, Itoh Y, Okuyama K, Sakiyama S, Isono K 1996 Reduced messenger RNA expression level of p21 CIP1 in human colorectal carcinoma tissues and its association with p53 gene mutation. Int J Cancer 69:259-264
38. Maki CG, Howley PM 1997 Ubiquitinization of p53 and p21 is differentially affected by ionizing and UV radiation. Mol Cell Biol 17:355-363
39. Alessandrini A, Chiaur DS, Pagano M 1997 Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia 11:342-345
40. kip1 accumulation during the cell cycle. Science 271:1861-1864